Nitinol Stent Implantation in TASC A and B Superficial Femoral Artery Lesions:<b>The Femoral Artery Conformexx Trial (FACT)</b>

Abstract

This study of patients with SFA lesions documented favorable outcomes using nitinol stents in TASC-II A or B lesions after 1 year. The study was underpowered to prove superiority of the Conformexx nitinol stent design compared to historical balloon only or Luminexx 3 stent groups.